Related Experiment Video
Updated: Jun 21, 2025

08:16
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
6.7K
A Probabilistic Approach to Estimate the Temporal Order of Pathway Mutations Accounting for Intra-Tumor Heterogeneity
Menghan Wang1, Yanqi Xie2, Jinpeng Liu3,4
1Department of Statistics, University of Kentucky, Lexington, KY 40536, USA.
Cancers
|July 13, 2024
Summary
This study introduces PATOPAI, a new computational method to determine the order of cancer-driving pathway mutations. It accurately sequences these mutations by accounting for intra-tumor heterogeneity (ITH).
Area of Science:
- Oncology
- Computational Biology
- Genomics
Background:
- Cancer develops through accumulating somatic mutations in key biological pathways.
- Understanding the sequence of these mutations is vital for cancer research and therapy development.
- Existing computational methods often overlook intra-tumor heterogeneity (ITH), limiting their accuracy in determining mutation order.
Purpose of the Study:
- To develop a novel computational approach for accurately estimating the temporal order of pathway mutations during tumorigenesis.
- To address the limitations of current methods by incorporating intra-tumor heterogeneity (ITH).
- To leverage pathway and functional annotation information for improved mutation ordering.
Main Methods:
- Proposed PATOPAI, a probabilistic method for estimating pathway mutation order.
- Incorporated ITH, pathway, and functional annotation data into the model.
- Utilized a maximum likelihood approach to determine probable mutation sequences consistent with tumor phylogeny.
Main Results:
- PATOPAI successfully estimates the temporal order of pathway mutations.
- The method effectively incorporates ITH information for more accurate sequencing.
- Demonstrated utility on whole exome sequencing data from The Cancer Genome Atlas (TCGA) across multiple cancer types.
Conclusions:
- PATOPAI offers an improved approach to understanding cancer development by accurately ordering pathway mutations.
- Accounting for ITH is crucial for precise reconstruction of mutational timelines in cancer.
- The method has broad applicability for analyzing cancer genomics data and identifying therapeutic targets.
More Related Videos
Related Concept Videos
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K

